Methods for treating bipolar disorder

Patent metadata

Field	Value
Publication number	US-9610274-B2
Application number	US-82750510-A
Country	US
Kind code	B2
Filing date	Jun 30, 2010
Priority date	Jun 30, 2010
Publication date	Apr 4, 2017
Grant date	Apr 4, 2017

Abstract

The invention is directed to a method of treating bipolar disorder in a subject, comprising administering a therapeutically effective amount of a carbamate compound, or pharmaceutically acceptable salt or amide thereof.

First claim

What is claimed is:

1. A method of diminishing manic symptoms in a mammal suffering from bipolar disorder, wherein the mammal is exhibiting manic symptoms of bipolar disorder, comprising the administration of a therapeutically effective amount of a compound having structural Formula (1) or a pharmaceutically acceptable salt thereof, to a mammal in need thereof:

wherein,
R is hydrogen;
x is 1; and
R 1 and R 2 are hydrogen,
to thereby diminish the manic symptoms in the mammal suffering from bipolar disorder.

2. The method of claim 1 , wherein the compound having structural Formula (1) is an enantiomer substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of the compound having structural Formula (1) predominates.

3. The method of claim 2 , wherein one enantiomer predominates to the extent of about 90% or greater.

4. The method of claim 3 , wherein one enantiomer predominates to the extent of about 98% or greater.

5. The method of claim 2 , wherein the enantiomer is (S) or (L) enantiomer as represented by Structural Formula (1a):

6. The method of claim 5 , wherein one enantiomer predominates to the extent of about 90% or greater.

7. The method of claim 6 , wherein one enantiomer predominates to the extent of about 98% or greater.

8. The method of claim 2 , wherein the enantiomer is (R) or (D) enantiomer, as represented by Structural Formula (1b):

9. The method of claim 8 , wherein one enantiomer predominates to the extent of about 90% or greater.

10. The method of claim 9 , wherein one enantiomer predominates to the extent of about 98% or greater.

11. The method of claim 8 , wherein the enantiomer is (R)-(beta-amino -benzenepropyl)carbamate.

12. The method of claim 11 , wherein the enantiomer of (R)-(beta-amino -benzenepropyl)carbamate predominates to the extent of about 90% or greater.

13. The method of claim 12 , wherein the enantiomer of (R)-(beta-amino -benzenepropyl)carbamate predominates to the extent of about 98% or greater.

Assignees

• Lee Sung James
• Melnick Susan Marie
• Sk Biopharmaceuticals Co Ltd

Inventors

• Lee Sung James
• Melnick Susan Marie

Classifications

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P25/20

  Hypnotics; Sedatives · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61K31/27 Primary

  of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title